| Autor: |
Sun CQ; a Department of Urology and Winship Cancer Institute , Emory University , Atlanta , Georgia., Arnold RS; a Department of Urology and Winship Cancer Institute , Emory University , Atlanta , Georgia., Hsieh CL; b Department of Molecular Medicine , China Medical University Hospital , Taipei , Taiwan., Dorin JR; c Center for Inflammation Research , University of Edinburgh , Edinburgh , UK., Lian F; d Emory University School of Medicine , Emory University , Atlanta , Georgia., Li Z; e School of Medicine , Central South University , Changsha City , Human Province , P. R. China., Petros JA; a Department of Urology and Winship Cancer Institute , Emory University , Atlanta , Georgia.; f Atlanta Veterans Affairs Medical Center , Atlanta , Georgia. |
| Abstrakt: |
Human beta-defensin-1 (hBD-1) is one of a number of small cationic host-defense peptides. Besides its well-known broad-spectrum antimicrobial function, hBD-1 has recently been identified as a chromosome 8p tumor-suppressor gene. The role of hBD-1 in modulating the host immune response to oncogenesis, associated with cell signaling and potential therapeutic applications, has become increasingly appreciated over time. In this study, multiple approaches were used to illustrate hBD-1 anti-tumor activities. Results demonstrate that hBD-1 peptide alters human epidermal growth factor receptor 2 (HER2) signal transduction and represses retroviral-mediated transgene expression in cancer cells. Loss of orthologous murine defense-1 (mBD1) in mice enhances nickel sulfate-induced leiomyosarcoma and causes mouse kidney cells to exhibit increased susceptibility to HPV-16 E6/7-induced neoplastic transformation. Furthermore, for the first time, a novel function of the urine-derived hBD-1 peptide was discovered to suppress bladder cancer growth and this may lead to future applications in the treatment of malignancy. |
